Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 260Lymphoma, Non-Hodgkin 205Leukemia, Lymphocytic, Chronic, B-Cell 193Lymphoma, Large B-Cell, Diffuse 187Lymphoma, Follicular 168Lymphoma, Mantle-Cell 134Leukemia 81Lymphoma, B-Cell, Marginal Zone 80Burkitt Lymphoma 54Waldenstrom Macroglobulinemia 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, B-Cell 47Lymphoma, Large-Cell, Immunoblastic 42Hodgkin Disease 39Recurrence 35Lymphoma, Large-Cell, Anaplastic 18Multiple Myeloma 16Neoplasms 13Myelodysplastic Syndromes 12Hematologic Neoplasms 12Leukemia, Myeloid, Acute 11Lymphoma, T-Cell 9Intraocular Lymphoma 9Dendritic Cell Sarcoma, Interdigitating 9Leukemia, Prolymphocytic 7Neoplasms, Plasma Cell 6Leukemia, Hairy Cell 6Leukemia, B-Cell 6Graft vs Host Disease 6Arthritis, Rheumatoid 6

Interventions

iniparib 2Poly(ADP-ribose) Polymerase Inhibitors 2Dexamethasone 2amminedichloro(2-methylpyridine)platinum(II) 1Sodium Chloride 1Rituximab 1Lenalidomide 1Cetirizine 1Calcium Dobesilate 1Blood Specimen Collection 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hypersensitivity × Rituximab × Clear all
NCT01206777 2017-12-20

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
52 enrolled 4 charts

Hypersensitivity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡